GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences:
TD Cowen 45th Annual Health Care Conference: | |||||||||
Fireside Chat | |||||||||
Date: | Tuesday, March 4, 2025 | ||||||||
Time: | 9:10 – 9:40 a.m. Eastern Time (ET) | ||||||||
Location: | Boston, MA | ||||||||
Conference | |||||||||
Event: | Investor Meetings | ||||||||
Date: | Tuesday, March 4, 2025 | ||||||||
Leerink Partners 2025 Global Healthcare Conference: | |||||||||
Presentation | |||||||||
Date: | Tuesday, March 11, 2025 | ||||||||
Time: | 3:40 – 4:10 p.m. ET | ||||||||
Location: | Miami Beach, FL | ||||||||
Conference | |||||||||
Event: | Investor Meetings | ||||||||
Date: | Tuesday, March 11, 2025 | ||||||||
Jefferies Biotech on the Beach Summit: | |||||||||
Conference | |||||||||
Event: | Investor Meetings | ||||||||
Date: | Wednesday, March 12, 2025 | ||||||||
Location: | Miami Beach, FL | ||||||||
A webcast of the fireside chat and presentation will be available through the Events and Presentations page of the Company's website at ir.novavax.com, with replays available for 30 days after the conferences.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines and its cutting-edge technology platform, including a protein-based nanoparticle and Matrix-M™ adjuvant. The Company's growth strategy is focused on building new and diversified partnerships via the out-licensing of its technology platform and vaccine assets earlier in the development process. These strategic collaborations are fueled by smart investments in a growing early-stage pipeline starting with the Company's core expertise in infectious disease and potentially expanding into other disease areas. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Giovanna Chandler
202-709-5563
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.42 |
| Daily Change: | -0.28 -4.18 |
| Daily Volume: | 4,966,254 |
| Market Cap: | US$1.030B |
April 29, 2025 April 15, 2025 March 11, 2025 February 27, 2025 December 13, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
